India Pharma Outlook Team | Friday, 20 May 2022
The United States Food and Drug Administration (USFDA) has granted final approval to Glenmark PharmaceuticalsInc., USA (Glenmark) for Abiraterone Acetate Tablets.
Zytiga1 tablets, 500 mg is the generic version of Janssen Biotech Inc.'s Zytiga1 tablets, 500 mg. According to IQVIATM sales data, the Zytiga tablets, 500 mg market had annual sales of approximately $260.2million in the 12 months ending March 2022. Glenmark's current portfolio includes 173 products that are authorised for distribution in the United States market, as well as 49 ANDAs awaiting FDA approval in the United States.
Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, in addition to these internal filings.
, CDSCO.jpg)
